Effect of the drug Rosuvastatin in lowering the risk of heart disease in diabetes patients
- Conditions
- Health Condition 1: null- Type 2 Diabetes Mellitus patients
- Registration Number
- CTRI/2017/09/009695
- Lead Sponsor
- Sri Venkateswara Institute of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 40
Newly diagnosed male patients with T2DM aged between 40-70 years as per the revised ADA criteria (37):i.e
i) Fasting plasma glucose =126mg/dL (7.0mmol/L)
ii) 2 hour plasma glucose =200mg/dL (11.1mmol/L)
iii) Glycosylated hemoglobin (HbA1c) >6.5% (48 mmol/mol)
Patients with T2DM on oral antidiabetic treatment and with LDL levels > 75 mg/dl will be included.
Female patients with type 2 Diabetes mellitus
Patients with other forms of Diabetes (T1DM, Gestational diabetes mellitus)
Those on insulin therapy
Thyroid disorders not on treatment
Those on pioglitazone
Liver and kidney diseases
Other inflammatory diseases
Acute illness
Malignancy
Alcoholics
Current smoking
On cholesterol lowering drugs
Individuals who are not willing to participate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Determine the anti-atherogenic effects of rosuvastatin namely its anti-oxidant and anti-inflammatory effects in patients with type 2 diabetes mellitusTimepoint: 2
- Secondary Outcome Measures
Name Time Method Determine the lipid lowering capacity of rosuvastatin by assessment of lipid profile in patients with T2DM before and after 12 weeks of Rosuvastatin treatmentTimepoint: 2